Table 5.
Overview of treatment-related adverse events.
| Pembrolizumab group (n = 49) | Bevacizumab group (n = 53) | |||
|---|---|---|---|---|
| Any grade | Grade 3-5 | Any grade | Grade 3-5 | |
| Any event, n (%) | 46 (93.9) | 25 (51.0) | 50 (94.3) | 17 (32.1) |
| Event related to treatment discontinuation, n (%) | 1 (2.0) | 1 (2.0) | 2 (3.8) | 1 (1.9) |
| Event related to death, n (%) | 1 (2.0) | 1 (2.0) | 0 | 0 |
| Event occurring in > 5% of patients in either group, n (%) | ||||
| Leukopenia | 20 (40.8) | 6 (12.2) | 15 (28.3) | 2 (3.8) |
| Anemia | 17 (34.7) | 5 (10.2) | 29 (54.7) | 3 (5.7) |
| Fatigue | 15 (30.6) | 0 | 13 (24.5) | 0 |
| Neutropenia | 13 (26.5) | 6 (12.2) | 19 (35.8) | 1 (1.9) |
| Thrombocytopenia | 12 (24.5) | 4 (8.2) | 17 (32.1) | 5 (9.4) |
| Elevated aminotransferase | 10 (20.4) | 1 (2.0) | 25 (47.2) | 1 (1.9) |
| Pyrexia | 7 (14.3) | 0 | 15 (28.3) | 0 |
| Rash | 6 (12.2) | 0 | 7 (13.2) | 0 |
| Abnormal coagulation parameters | 6 (12.2) | 0 | 24 (45.3) | 2 (3.8) |
| Constipation | 6 (12.2) | 0 | 9 (17.0) | 0 |
| Pneumonitis | 5 (10.2) | 1 (2.0) | 0 | 0 |
| Nausea | 4 (8.2) | 1 (2.0) | 2 (3.8) | 0 |
| Elevated blood creatinine | 3 (6.1) | 0 | 10 (18.9) | 0 |
| Vomiting | 3 (6.1) | 0 | 2 (3.8) | 0 |
| Hypothyroidism | 3 (6.1) | 0 | 0 | 0 |
| Abnormal electrocardiogram | 1 (2.0) | 0 | 9 (17.0) | 1 (1.9) |
| Proteinuria | 1 (2.0) | 0 | 7 (13.2) | 1 (1.9) |
| Hemorrhage | 1 (2.0) | 0 | 13 (24.5) | 2 (3.8) |
| Hypertension | 0 | 0 | 8 (15.1) | 1 (1.9) |
The events are listed in descending order of frequency in the pembrolizumab group.